Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Cardiol Therapeutics (CRDL) Accumulated Depreciation & Amortization (2020 - 2025)

Cardiol Therapeutics filings provide 3 years of Accumulated Depreciation & Amortization readings, the most recent being $62210.1 for Q4 2022.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 7.14% to $62210.1 in Q4 2022 year-over-year; TTM through Dec 2022 was $62210.1, a 7.14% decrease, with the full-year FY2022 number at $62210.1, down 7.14% from a year prior.
  • Accumulated Depreciation & Amortization hit $62210.1 in Q4 2022 for Cardiol Therapeutics, down from $66992.5 in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $66992.5 in Q4 2021 to a low of $62210.1 in Q4 2022.
  • Median Accumulated Depreciation & Amortization over the past 3 years was $64773.2 (2020), compared with a mean of $64658.6.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: grew 3.43% in 2021 and later dropped 7.14% in 2022.
  • Cardiol Therapeutics' Accumulated Depreciation & Amortization stood at $64773.2 in 2020, then grew by 3.43% to $66992.5 in 2021, then fell by 7.14% to $62210.1 in 2022.
  • The last three reported values for Accumulated Depreciation & Amortization were $62210.1 (Q4 2022), $66992.5 (Q4 2021), and $64773.2 (Q4 2020) per Business Quant data.